Changes in pegaptanib labeling prompted by adverse reactions

Charters, Lynda
May 2006
Ophthalmology Times;5/15/2006, Vol. 31 Issue 10, p8
Trade Publication
The article focuses on the changes in the product labeling for pegaptanib sodium injection made by OSI Pharmaceuticals Inc., Eyetech Pharmaceuticals Inc. and Pfizer Inc. The injection was approved by the United States Food and Drug Administration for the treatment of neovascular age-related macular degeneration in December 2004.


Related Articles

  • At OSI, a $935M poke in the Eye(tech). Harrell, Jeremy // Long Island Business News (7/1993 to 5/2009);11/10/2006, Vol. 53 Issue 51, p5A 

    The article reports developments surrounding the $935-million investment in cash and stock of OSI Pharmaceuticals Inc. to acquire the macular degeneration drug called Macugen from Eyetech Pharmaceuticals Inc. in Melville, New York in November 2005. At that time, analysts and stockholders...

  • Pegaptanib sodium injection available for treatment of AMD-related CNV. Guttman, Cheryl // Ophthalmology Times;1/15/2005, Vol. 30 Issue 2, p1 

    This article reports that the FDA approved pegaptanib sodium injection by Macugen, Eyetech Pharmaceuticals and Pfizer Ophthalmics for the treatment of neovascular age-related macular degeneration (AMD) on December 17. With the regulatory agency's decision, pegaptanib sodium became the first...

  • Mergers & Acquisitions Update.  // PharmaWatch: Biotechnology;Oct2005, Vol. 4 Issue 10, p16 

    The article presents information about the latest mergers and acquisitions in the biotechnology industry. It is reported that Pfizer Inc. has reached an agreement to acquire Bioren, a California-based firm specializing in technology for optimizing antibodies, for an undisclosed amount. Antibody...

  • Injection approved for macular degeneration.  // Drug Topics;1/10/2005, Vol. 149 Issue 1, p8 

    Reports on the approval of Pegaptanib sodium injection 0.3 mg from Eyetech Pharmaceuticals/Pfizer, for the treatment of neovascular age-related macular degeneration.

  • FDA Approves Eyetech/Pfizers Macugen.  // Review of Ophthalmology;Jan2005, Vol. 12 Issue 1, p4 

    The article reports that the U.S. food and Drug Administration has approved Macugen injection for the treatment of neovascular age-related macular degeneration. The injection has been developed by Eyetech Pharmaceuticals Inc. and Pfizer Inc. Macugen is the first in a new class of ophthalmic...

  • Retina Specialists: A Grim View of AMD.  // Review of Ophthalmology;Aug2004, Vol. 11 Issue 8, p12 

    Presents results from the online survey regarding wet age-related macular degeneration (AMD), commissioned by the Eyetech Pharmaceuticals and Pfizer, in consultation with the Lighthouse International. Percentage of specialists who were alarmed by the increasing number of cases of wet AMD; Effect...

  • New Eye Drug Approved. Mirasol, Feliza // Chemical Market Reporter;1/10/2005, Vol. 267 Issue 2, p10 

    Reports on the approval of the U.S. Food and Drug Administration to new eye drug Macugen of Eyetech Pharmaceuticals Inc. and co-developer Pfizer Inc. Use of Macugen in the treatment of neovascular age-related macular degeneration; Price of the drug; Development of Macugen.

  • Macugen account goes to Medicus. Arnold, Matthew // Medical Marketing & Media;May2004, Vol. 39 Issue 5, p10 

    Reports that Pfizer and Eyetech Pharmaceuticals have appointed Medicus New York to handle professional advertising for their co-marketed Macugen drug for macular degeneration. Account is Medicus Group's first formal assignment from Pfizer; Parent firm Publicis Groupe's work with Pfizer in the...

  • AMD: A Revolution In Therapy Begins. Rosenfeld, Philip // Review of Ophthalmology;Mar2005, Vol. 12 Issue 3, p96 

    Assesses the effectiveness of Macugen, an ophthalmic drug from Eyetech Pharmaceuticals Inc. and Pfizer Inc., that specifically targets the vascular endothelial growth factor (VEGF) to treat age-related macular degeneration. Correlation between elevated levels of VEGF and various diseases that...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics